Adimab's latest partner program to receive approval is GSK's Exdensur (depemokimab), approved in the US for the treatment of severe asthma with an eosinophilic phenotype and in the UK and Japan for ...
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...
New Study Shows SIK1 Strengthens Antiviral Immunity to Limit EV-D68–Induced Asthma Exacerbations Asthma is a chronic ...
About Kinaset Therapeutics, Inc. Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. With founding investors 5AM ...
Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...
Explore the most influential drug approvals of 2025, highlighting FDA-cleared therapies that impact public health and clinical care.
China: Researchers have found in a new meta-analysis that mepolizumab is an effective and safe treatment for severe ...
GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps: London, UK Wednesday, January 7, 2026, 10:00 Hrs [IST] GSK plc an ...
The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...
China NMPA approves GSK’s Nucala to treat adults with chronic obstructive pulmonary disease: London, UK Tuesday, January 6, 2026, 10:00 Hrs [IST] GSK plc announced that China’ ...
Dr Lata BichileMK, a 42-year-old engineer, walked into my OPD along with his wife in August 2023. He had been experiencing ...
Statins were linked to decreased risk for acute asthma exacerbations in mild asthma and had a significant protective effect in Black patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback